Roche’s Tecentriq meets targets in lung cancer trial

ZURICH (Reuters) - A combination of Roche's Tecentriq immunotherapy with chemotherapy helped people with a form of lung cancer live significantly longer than patients on chemotherapy alone, a late-sta…
Read the full story: Reuters: Health News